Abstract:Endothelia progenitor cell (EPC)-based revascularization therapies have shown promise for the treatment of myocardial ischemic injury. However, applications and efficacy are limited by the relatively inefficient recruitment of endogenous EPCs to the ischemic area, while implantation of exogenous EPCs carries the risk of tumorigenicity. In this study, we developed a therapeutic protocol that relies on the capacity of neutrophils (NEs) to target lesions and release preloaded EPC-binding molecules for high efficiency capture. Neutrophils were loaded with superparamagnetic iron oxide nanoparticles conjugated to an antibody against the EPC surface marker CD34 (SPIO-antiCD34/NEs), and the therapeutic efficacy in ischemic mouse heart following SPIO-antiCD34/NEs injection was monitored by SPIO-enhanced magnetic resonance imaging (MRI). These SPIO-antiCD34/NEs exhibited unimpaired cell viability, superoxide generation, and chemotaxis in vitro as well as satisfactory biocompatibility in vivo. In a mouse model of acute myocardial infarction (MI), SPIO-antiCD34 accumulation could be observed 0.5 h after intravenous injection of SPIO-antiCD34/NEs. Moreover, the degree of CD133+ EPC accumulation at MI sites was three-fold higher than in control MI model mice, while ensuing microvessel density was roughly two-fold higher than controls and left ventricular ejection fraction was > 50%. Therapeutic cell biodistribution, MI site targeting, and treatment effects were confirmed by SPIO-enhanced MRI. This study offers a new strategy to improve the endogenous EPC-based myocardial ischemic injury repair through NEs mediated SPIO nanoparticle conjugated CD34 antibody delivery and imaging.Statement of SignificanceThe efficacy of endogenous endothelial progenitor cell (EPC)-based cardiovascular repair therapy for ischemic heart damage is limited by relatively low EPC accumulation at the target site. We have developed a method to improve EPC capture by exploiting the strong targeting ability of neutrophils (NEs) to ischemic inflammatory foci and the capacity of these treated cells to release of preloaded cargo with EPC-binding affinity. Briefly, NEs were loaded with superparamagnetic iron oxide nanoparticles conjugated to an antibody against the EPC surface protein CD34 (SPIO-antiCD34). Thus, we explored sites targeting with nanocomposites cargo for non-invasive EPCs interception and therapy tracking. We demonstrate that SPIO-antiCD34 released from NEs can effectively capture endogenous EPCs and thereby promote heart revascularization and functional recovery in mice. Moreover, the entire process can be monitored by SPIO-enhanced magnetic resonance imaging including therapeutic cell biodistribution, myocardial infarction site targeting, and tissue repair.

Non-Invasive Imaging Of Endothelial Progenitor Cells In Tumor Neovascularization Using A Novel Dual-Modality Paramagnetic/Near-Infrared Fluorescence Probe

Magnetic Resonance Imaging of Magnetically Labeled Endothelial Progenitor Cells Homing to the Injured Endothelium

Multi-modality in vivo imaging of endothelial progenitor cells with a novel probe in tumor neovascularization

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

Multimodality imaging of endothelial progenitor cells with a novel multifunctional probe featuring positive magnetic resonance contrast and near-infrared fluorescence.

Noninvasive Evaluation of the Migration Effect of Transplanted Endothelial Progenitor Cells in Ischemic Muscle Using a Multimodal Imaging Agent

Magnetic resonance tracking of endothelial progenitor cells labeled with alkyl-polyethylenimine 2 kDa/superparamagnetic iron oxide in a mouse lung carcinoma xenograft model.

Non-invasive Monitoring of Transplanted Endothelial Progenitor Cells in Diabetic Ischemic Stroke Models

Efficient Nano Iron Particle-Labeling and Noninvasive MR Imaging of Mouse Bone Marrow-Derived Endothelial Progenitor Cells

In Vivo Serial Mr Imaging of Magnetically Labeled Endothelial Progenitor Cells Homing to the Endothelium Injured Artery in Mice

Longitudinal Monitoring Of Tumor Antiangiogenic Therapy With Near-Infrared Fluorophore-Labeled Agents Targeted To Integrin Alpha(V)Beta(3) And Vascular Endothelial Growth Factor

Magnetic resonance and near-infrared imaging using a novel dual-modality nano-probe for dendritic cell tracking in vivo.

Targeted trapping of endogenous endothelial progenitor cells for myocardial ischemic injury repair through neutrophil-mediated SPIO nanoparticle-conjugated CD34 antibody delivery and imaging

Noninvasive Monitoring of Early Antiangiogenic Therapy Response in Human Nasopharyngeal Carcinoma Xenograft Model Using MRI with RGD-conjugated Ultrasmall Superparamagnetic Iron Oxide Nanoparticles

Efficient Labeling Of Endothelial Progenitor Cells With Superparamagnetic Iron Oxide Particles For In Vivo Cell Tracking

Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin α v β 3 and vascular endothelial growth factor

Superparamagnetic Iron Oxide Nanoparticles As Magnetic Resonance Imaging Contrast Agents and Induced Autophagy Response in Endothelial Progenitor Cells.

Bimodal Imaging‐Visible Nanomedicine Integrating CXCR4 and VEGFa Genes Directs Synergistic Reendothelialization of Endothelial Progenitor Cells

Identification and 7.0 T Magnetic Resonance Imaging of Murine Bone Marrow-Derived Endothelial Progenitor Cells

In Vitro Labeling Of Endothelial Progenitor Cells Isolated From Peripheral Blood With Superparamagnetic Iron Oxide Nanoparticles

Noninvasive Monitoring of Microvascular Changes with Partial Irradiation Using Dynamic Contrast-Enhanced and Blood Oxygen Level-Dependent Magnetic Resonance Imaging.